Location: United States, Maryland, Cambridge
Employees: 11-50
Total raised: $6M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | K20 Fund | k20fund.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.04.2021 | Series A | $6M | - |
Mentions in press and media 8
| Date | Title | Description |
| 10.03.2026 | OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting | OS Therapies on track to complete clinical data submission by the end of Q1 2026 The most recent publicly disclosed PRV transaction occurred in February 2026 at a reported value of $205 million. FDA's elevated meeting status signals transit... |
| 06.02.2026 | OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program for Osteosarcoma Therapies | Innovation is urgent and direly needed as pediatric cancers remain the leading disease-based cause of pediatric death in the United States. Mikaela's legacy through this legislation will accelerate critical opportunities for research and th... |
| 03.02.2026 | OS Therapies Initiates FDA BLA Filing for OST-HER2 to Prevent or Delay Recurrent Pulmonary Metastatic Osteosarcoma | At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous osteosarcoma in canines Company remains ... |
| 16.01.2026 | OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 | Pre-specified pathway analysis strategy developed as a result of immune biomarker pathway data generated from 118-patient canine metastatic osteosarcoma study published in February 2025 demonstrates translational power of Comparative Oncolo... |
| 14.01.2026 | OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary | OSTX shareholders expected to receive one (1) share of OSAH for every ten (10) shares of OSTX owned as of the expected to-be-determined 1H/2026 record date OSAH to focus primarily on the re-establishment of USDA conditional approval and com... |
| 26.12.2024 | OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online | OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online OS Therapies Joins the B2i Digital Featured Companies Program Digital Marketing Campaign to Highlight Clinical-Stage Cancer Innovation OST-HER2 that activates ce... |
| 21.04.2021 | OS Therapies Raises $6M in Series A Funding | OS Therapies, a Cambridge, Md.-based clinical-stage biopharmaceutical company, closed a $6 million Series A round of funding. Backers were not disclosed. The company will use the funds to continue to advance its products. Led by Dr. Robert ... |
| 20.04.2021 | OS Therapies Closes $6 Million in Series A Funding | OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS) and other deadly cancers in kids and adults including ovarian, esophageal, endometrial a... |